The world’s largest pharmaceutical company, Pfizer, has signed a research collaboration with biosciences firm, Sangamo, for the production of enhanced proteins.
The exact financial details of the deal have not been disclosed, but Pfizer has committed to funding research at Sangamo, which in turn will use its zinc finger DNA-binding protein technology to create new cell lines and technology for the quicker production of cell lines.
“ZFP transcription factors are used to regulate genes expressing protein pharmaceuticals and we can engineer zinc finger nucleases to facilitate the efficient generation of production cell lines with altered traits,” explained Edward Lanphier, Sangamo’s president and chief executive.
